Substance Use Disorder · Opioid Use DisorderTrial Updateclinicalmid-term

VA Study to Test Values-Based Intervention for Veterans in Buprenorphine Treatment

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/24/2026, 6:02:55 AM

Assessment confidence: 49% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

This study represents a significant advancement in addressing the psychological and social challenges faced by Veterans undergoing buprenorphine treatment for opioid use disorder. If successful, it could lead to the development of integrated treatment protocols that enhance overall therapeutic outcomes, which is critical for improving patient care in this demographic. Regulatory context from FDA (FDA AP — BUPRENORPHINE (SUPPL)) supports the near-term read. Assessment grounded in 14 ranked evidence items (3 high-relevance).

Strategic Assessment

If successful, this approach may lead to new treatment protocols that integrate psychological support with pharmacotherapy for opioid use disorder. The strongest clinical anchor is A Brief Values Intervention to Support Veterans in Early Buprenorphine Treatment (ClinicalTrials.gov), sub-indication match (pain). In pain, 6 regulatory and 4 competitive items passed relevance filtering for Veterans with Opioid Use Disorder.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217).

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — BUPRENORPHINE (SUPPL) (FDA). Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. If the intervention proves effective, it may prompt regulatory bodies to consider new treatment guidelines that incorporate psychological support into existing pharmacotherapy frameworks.

Key Risks

Elevated medium regulatory exposure for Veterans with Opioid Use Disorder could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (A Brief Values Intervention to Support Veterans in Early Buprenorphine Treatment) could weigh on Veterans with Opioid Use Disorder through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

Successful integration of psychological support with pharmacotherapy could reshape treatment paradigms, potentially increasing market share for companies involved in opioid treatment solutions.
If successful, this approach may lead to new treatment protocols that integrate psychological support with pharmacotherapy for opioid use disorder.

What Would Change This Assessment

This becomes more urgent if Monitor results from the pilot randomized controlled trial and feedback from participants regarding treatment effectiveness.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — BUPRENORPHINE (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUPRENORPHINE (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly
MHRAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves First Single-Dose Generic Treatment for Influenza
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Over-The-Counter (OTC) Heartburn Treatment
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Brief Values Intervention to Support Veterans in Early Buprenorphine Treatment
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Developing and Testing Innovative Care Pathways for Screening and Treatment of OUD/PTSD in Jails
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Deep Brain Stimulation Effects In Patients With Opioid Use Disorder
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region
ClinicalTrials.govmedium relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
A Project to Test the Efficacy and Safety of An Innovative Treatment for Opiate Use Disorders.
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Integrated CBT to Improve Functioning in Veterans With Anxiety and Substance Use
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizermedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
Merck's Tulisokibart Achieves Key Endpoints in Phase 3 UC Study
Humanexa Signalsmedium relevance
Sponsor/company relevance (Merck)

Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
The impact of (poly)phenol-rich sugarcane extract intervention on markers of gastrointestinal integrity and systemic inflammation in response to exertional-heat stress.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Microneedle-based injection of Fungizone/Amphotericin B: an effective treatment for American cutaneous leishmaniasis in mice.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Veterans with Opioid Use Disorder
Buprenorphine treatment protocols

Commercial impact

medium

Successful integration of psychological support with pharmacotherapy could reshape treatment paradigms, potentially increasing market share for companies involved in opioid treatment solutions.

Regulatory impact

medium

If the intervention proves effective, it may prompt regulatory bodies to consider new treatment guidelines that incorporate psychological support into existing pharmacotherapy frameworks.

What to watch

Monitor results from the pilot randomized controlled trial and feedback from participants regarding treatment effectiveness.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.